Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia’s latest clinical results follow two earlier [...]

Excaliard Pharmaceuticals, Inc. announced the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders. The U.S. multicenter trials will test the efficacy, safety, and tolerability of EXC 001 in two different models to evaluate the improvement [...]

Actelion Ltd (SIX: ATLN) announced today that the first phase III study with almorexant (RESTORA 1) has met its primary endpoint, superiority of the dual orexin receptor antagonist almorexant compared to placebo on objective and subjective wake after sleep onset (WASO). The finding was highly significant (p<0.001). In addition, several secondary endpoints of the study [...]

Addex Pharmaceuticals (SWISS: ADXN) announced that it has decided to end prematurely the migraine prevention study 206.
Routine safety monitoring of blinded data in study 206 has revealed an incidence of abnormalities of liver function tests that is higher than expected in this population. The abnormalities are apparent from day 28 of dosing but the incidence [...]

DURECT Corporation (Nasdaq: DRRX) announced positive results from a 60 patient Phase IIb clinical trial of POSIDUR(TM), a proprietary product under development for the treatment of post-surgical pain. Top line results from this study of patients undergoing arthroscopic shoulder surgery showed a consistent reduction of pain scores (as measured by mean pain intensity on movement [...]